Loading...
XLON
0RC6
Market cap1.53bUSD
Jun 07, Last price  
33.42EUR
Name

Pharma Mar SA

Chart & Performance

D1W1MN
XLON:0RC6 chart
P/E
22.30
P/S
3.33
EPS
1.50
Div Yield, %
—
Shrs. gr., 5y
-0.97%
Rev. gr., 5y
15.30%
Revenues
175m
+10.56%
471,00076,240,00085,459,000105,260,000123,387,000153,508,000152,486,000138,229,000140,476,000148,686,000192,814,000180,943,000179,337,000162,163,00085,819,000269,961,000229,831,000196,343,000158,153,000174,855,000
Net income
26m
+2,197.71%
42,000-48,648,000-50,665,000-43,737,000-28,136,000-12,332,000-1,373,0006,593,00011,322,00013,115,0006,588,000-24,082,000-26,745,000-5,535,000-9,180,000137,262,00092,859,00049,356,0001,137,00026,125,000
CFO
6m
P
-33,034,000-56,114,000-49,158,000-35,656,000-22,666,000-21,899,000-4,282,0006,319,00016,345,00022,109,00011,101,000-8,414,000-1,459,000-16,340,000-26,137,000278,942,00025,677,00038,321,000-13,446,0006,027,000
Dividend
Jun 12, 20240.65 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
URL
https://www.pharmamar.com/es/
IPO date
Nov 02, 2015
Employees
515
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT